-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Poster III

Program: Oral and Poster Abstracts
Type: Poster
Hematology Disease Topics & Pathways:
AML, apoptosis, Biological, therapy sequence, CML, Diseases, Non-Biological, CMML, Combinations, Therapies, cellular interactions, chemotherapy, MDS, Biological Processes, enzyme inhibitors, MPN, Technology and Procedures, gene editing, Clinically relevant, genetic profiling, Myeloid Malignancies, hematopoiesis, pharmacology, flow cytometry, TKI, integrative -omics, stem cells, NGS, microenvironment, pathogenesis, pathways, signal transduction
Monday, December 7, 2020: 7:00 AM-3:30 PM

Amit Subedi, PhD1, Qiang Liu, PhD, BSc2, David Sharon, PhD3, Severine Cathelin, PhD1*, Gary D Bader4*, Changjiang Xu5*, Veronique Voisin, PhD6*, Angelo D'Alessandro, PhD7*, Eric R Lechman, Ph.D.1*, John E. Dick, PhD, FRS8, Mark D. Minden9, Jean C.Y. Wang, MD10 and Steven M Chan, MD, PhD11

1Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2Princess Margaret, University Health Network, Toronto, ON, Canada
3University Health Network, Toronto, ON, Canada
4The Donnelly Centre, University of Toronto, Toronto, ON, Canada
5The Donnelly Centre, University of Toronto, Toronto, Canada
6University of Toronto, Toronto, ON, Canada
7Department of Biochemistry and Molecular Genetics, University of Colorado Denver - Anschutz Medical Campus, Aurora, CO
8Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, ON, Canada
9Leukemia Program, Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
10Department of Medicine, Ontario Cancer Institute University Health Network, Toronto, ON, Canada
11Leukemia Program, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Xiaorong Gu, PhD1*, Rita Tohme, PhD2*, Mendel Goldfinger, MD3*, Benjamin K. Tomlinson, MD4,5, Nneha Sakre, PhD6*, Shannon Hanmer6*, Babal K. Jha, PhD1*, Jaroslaw P. Maciejewski, MD, PhD7, Amit Verma, MBBS3 and Yogenthiran Saunthararajah, MD1

1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
2Taussig Cancer Institute, Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
3Hematology/Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
4Adult Hematologic Malignancies & Stem Cell Transplant Section, University Hospitals Seidman Cancer Center, Cleveland, OH
5Case Western Reserve University, Cleveland, OH
6Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH
7Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Marie Lue Antony, PhD1,2*, Klara Noble-Orcutt, BS, MS1,2*, Yoonku Lee, MS1,2*, Oluwateniayo Ogunsan2*, Jeffrey Lee Jensen, MD, PhD2*, Fiona He, MD1,2 and Zohar Sachs, MD, PhD1,2

1Department of Medicine, Division of Hematology Oncology and Transplantation, University of Minnesota, Minneapolis, MN
2Masonic Cancer Center, University of Minnesota, Minneapolis, MN

Simona Pagliuca, MD1,2, Yihong Guan, PhD2*, Anand D. Tiwari, PhD2*, Dale Grabowski, BS2*, Carmelo Gurnari, MD2,3*, Cassandra M Kerr, MS2*, Sunisa Kongkiatkamon, MD2,4*, Metis Hasipek, PhD2*, Laila Terkawi2*, Misam Zawit, MBBS2*, Hassan Awada, MD2, Valeria Visconte, PhD2, Yogenthiran Saunthararajah, MD2, James G Phillips, PhD2*, Jaroslaw P. Maciejewski, MD, PhD5 and Babal K. Jha, PhD2*

1Université de Paris, Cleveland, OH
2Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH
3Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy
4Department of hematology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand
5Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH

Anna Wojcicki, BS1, Hee-Don Chae, PhD1*, Kyuho Han, PhD2*, Minyoung Youn, PhD1*, Mark C Wilkes, PhD1, Norman J. Lacayo, MD1, Michael Bassik, PhD2,3* and Kathleen M. Sakamoto, MD, PhD1

1Department of Pediatrics, Stanford University School of Medicine, Stanford, CA
2Department of Genetics, Stanford University, Stanford, CA
3Chemistry, Engineering, and Medicine for Human Health (ChEM-H), Stanford University, Stanford, CA

Diana O Treaba, MD1,2*, Dennis M Bonal3*, Anna D Chorzalska, PhD4*, Christoph Schorl, PhD5*, Kelsey Hopkins1*, John L Reagan, MD6, Peter Rintels, MD7, Peter J Quesenberry, MD8 and Patrycja M Dubielecka, PhD4

1Warren Alpert Medical School at Brown University, Providence, RI
2Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Providence, RI
3Signal Transduction Lab, Division of Hematology/Oncology at Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
4Signal Transduction Lab, Division of Hematology-Oncology, Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
5Genomics Core, Brown University, Providence, RI
6Division of Hematology/Oncology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI
7Division of Hematology/Oncology, Rhode Island Hospital and Warren Alpert Medical School at Brown University, Providence, RI
8Division of Hematology and Oncology, Rhode Island Hospital, Providence, RI

Bing Z Carter, PhD1, Po Yee Mak1*, Vivian Ruvolo, MS1*, Wenjing Tao1*, Paul Hughes2*, Xiaoyue Chen2*, PK Morrow3* and Michael Andreeff, MD, PhD1

1Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Oncology Research, Amgen Inc., Thousand Oaks, CA
3Amgen Inc., Thousand Oaks, CA

Scott Howard, MD1, Prashant Ramachandran Nair, B.Tech.2*, Himanshu Grover, M.S.2*, Anuj Tyagi, M.Sc.2*, Pallavi Kumari, M.Sc.2*, Samiksha Avinash Prasad, M.Sc.2*, Upasana Mitra, M.Sc.2*, Deepak Anil Lala, B.Tech.2*, Humera Azam, M.Sc.2*, Neha Gupta, M.Sc.2*, Subrat Mohapatra, M.Sc.2*, Poornachandra G, B.Tech.2*, Nirjhar Mundkur3*, Michele Dundas Macpherson, B.A.Sc.4* and Shweta Kapoor, M.Sc.2*

1University of Tennessee Health Science Center, Memphis, TN
2Cellworks Research India Private Limited, Bangalore, India
3Cellworks Group Inc., San Jose, CA
4Cellworks Group Inc., South San Francisco, CA

Kotoko Yamatani, MD1,2*, Tomohiko Ai, MD, PhD2*, Kaori Saito2*, Haeun Yang2*, Vivian Ruvolo, MS3*, Po Yee Mak3*, Sonoko Kinjo, PhD4*, Kazuho Ikeo, PhD4*, Hironori Harada, MD, PhD5, Kazuhiro Katayama, PhD6*, Takashi Miida, MD, PhD2*, Marina Konopleva, MD, PhD7, Weiguo Zhang, MD, PhD8, Bing Z Carter, PhD9, Yoshihide Hayashizaki, MD, PhD10*, Michael Andreeff, MD, PhD3 and Yoko Tabe, MD, PhD2,11

1Research Fellow of the Japan Society for the Promotion of Science, Tokyo, Japan
2Department of Clinical Laboratory Medicine, Graduate School of Medicine, Juntendo University, Tokyo, Japan
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Centers for Information Biology, National Institute of Genetics, Shizuoka, Japan
5Department of Hematology, Graduate School of Medicine, Juntendo University, Tokyo, Japan
6Laboratory of Molecular Targeted Therapeutics, School of Pharmacy, Nihon University, Chiba, Japan
7Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
8Section of Molecular Hematology and Therapy, Department of Leukemia, U.T.M.D. Anderson Cancer Center, Houston, TX
9Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Preventive Medicine & Diagnosis Innovation Program, RIKEN Center for Life Science Technoligies, Kanagawa, Japan
11Section of Molecular Hematology and Therapy, Department of Leukemia, MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH